ProQR's AX-0810 Phase 1 study demonstrates target engagement through an 8-fold increase in serum bile acids, validating the Axiomer...

Innovative Molecules launches Phase 2a Trial of Adibelivir for genital herpes, testing a helicase-primase inhibitor against acyclovir-resistant strains.

FDA backs Entera Bio's Phase 3 plan for oral EB613 osteoporosis drug, targeting injection-free anabolic therapy for postmenopausal women.

Phathom completes Phase 2 Vonoprazan EoE Trial ahead of schedule with 95 patients enrolled. Topline data expected by Q4...

Icon's Microsoft-Copilot partnership scales its Orbis AI platform enterprise-wide. For sites and sponsors mid-trial, the operational cost question starts...

GENFIT's GNS561 shows no dose-limiting toxicities in Phase 1b cholangiocarcinoma trial combining autophagy inhibition with MEK inhibition in KRAS-mutated...

Phathom enrolled 95 EoE patients across 41 U.S. sites ahead of schedule — in a disease where PPIs dominate...

FDA rejected cytisinicline over manufacturing issues at a third-party facility, not clinical safety, with resubmission planned for Q4 2026.

Lilly's $7.8B Centessa acquisition closes June 24—here's what site coordinators and ops leads must do before the IND transfers...

Revolution Medicines opens RASolute 305 Trial of zoldonrasib in RAS G12D pancreatic cancer, testing the G12D-selective inhibitor in the...